News | Structural Heart | October 05, 2023

Mayo Clinic Researchers Develop Calculation to Identify High-risk Moderate Aortic Stenosis Patients

According to new research published in Mayo Clinic Proceedings, calculating the patient's mean arterial pressure (AugMAP) is a simple and effective way to identify those patients who may benefit from more aggressive treatment strategies.

Getty Images


October 5, 2023 — Mayo Clinic researchers have developed a calculation that can help identify moderate aortic stenosis patients at higher risk of dying from the condition. According to new research published in Mayo Clinic Proceedings, calculating the patient's mean arterial pressure (AugMAP) is a simple and effective way to identify those patients who may benefit from more aggressive treatment strategies.

"Physiologically, AugMAP can be considered a marker of global left ventricular contractile function," says Chieh-Ju Chao, M.D., senior associate consultant in the Mayo Clinic Department of Cardiovascular Medicine and the study's first author. "AugMAP is easily calculated from the patient's blood pressure and mean aortic gradient, and we found that low AugMAP is associated with higher mortality in all moderate aortic stenosis patient subgroups."

Aortic stenosis is one of the most common cardiac valvular abnormalities, affecting about 5% of people older than 65 years. For most patients with moderate aortic stenosis, clinical guidelines call only for periodic monitoring with echocardiography, a test that uses sound waves to show how blood moves through the heart. However, growing evidence shows that patients with moderate aortic stenosis have poor longer-term survival rates and could benefit from earlier intervention.

The study looked at 4,563 patients with moderate aortic stenosis who were treated at Mayo Clinic from January 2010 through December 2020. The findings indicate that AugMAP is a better prognostic tool compared to other available measures and can detect early-stage left ventricular dysfunction before a decrease in left ventricular ejection fraction is observed. "With this information, we can identify patients at higher risk of mortality with current management strategies and initiate discussion about other treatment strategies," says Dr. Chao.

"Moderate aortic stenosis does carry a higher risk of morbidity and mortality compared to the general population based on several prior studies," says senior author Reza Arsanjani, M.D., a Mayo Clinic cardiologist. "Current guidelines recommend active surveillance although earlier intervention might benefit select patients. Our study could potentially identify high-risk individuals who might benefit from earlier intervention."

The authors say future studies should consider whether patients with lower AugMAP can benefit from earlier intervention rather than periodic monitoring.

For more information: https://www.mayoclinic.org/


Related Content

News | Structural Heart

February 20, 2024 — As New Jersey’s leading provider of high-quality cardiac procedures and diagnostic testing and an ...

Home February 20, 2024
Home
News | Structural Heart

February 15, 2024 — Abbott announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee ...

Home February 15, 2024
Home
News | Structural Heart

February 9, 2024 — Physicians in the Smidt Heart Institute at Cedars-Sinai have achieved two significant firsts ...

Home February 09, 2024
Home
News | Structural Heart

January 4, 2024 — Laguna Tech USA, a privately-held medical technology company dedicated to innovations in structural ...

Home January 04, 2024
Home
News | Structural Heart

December 12, 2023 — Think of them as the Energizer Bunnies of the heart, tiny natural batteries that keep this vital ...

Home December 12, 2023
Home
News | Structural Heart

October 31, 2023 — Edwards Lifesciences Corporation announced one-year results from CLASP IID, the first randomized ...

Home October 31, 2023
Home
News | Structural Heart

October 26, 2023 — Abbott announced data from late-breaking presentations showing the impact of its minimally invasive ...

Home October 26, 2023
Home
News | Structural Heart

October 19, 2023 — The Dib UltraNav Transseptal Catheter System, which houses a needle and ultrasound in one system for ...

Home October 19, 2023
Home
News | Structural Heart

October 19, 2023 — Edwards Lifesciences Corporation announced the company's EVOQUE tricuspid valve replacement system ...

Home October 19, 2023
Home
News | Structural Heart

October 12, 2023 — Franklin Mountain Medical announced today that the Dib UltraNav Transseptal Catheter System, which ...

Home October 12, 2023
Home
Subscribe Now